Last updated: May 18, 2026
What’s actually different
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA indication | Type 2 diabetes; cardiovascular risk reduction in T2D | Chronic weight management; cardiovascular risk reduction in obesity + CVD |
| Max dose | 2.0 mg/week | 2.4 mg/week |
| Pen strengths | 0.25, 0.5, 1.0, 2.0 mg | 0.25, 0.5, 1.0, 1.7, 2.4 mg |
| FDA approval year | 2017 | 2021 |
| Approval expansion | 2024: MACE reduction in T2D | 2024: MACE reduction in obesity + established CVD |
Same molecule, different label
This is a common pharma pattern — same active ingredient marketed under different brand names for different indications. The advantage for the manufacturer (Novo Nordisk) is separate clinical trials supporting separate indications, separate FDA labels, and ability to price differently.
Insurance coverage
Ozempic (T2D indication): generally covered by insurance for patients with type 2 diabetes diagnosis.
Wegovy (obesity indication): coverage is more variable. Many commercial plans exclude obesity drugs. Medicare doesn’t currently cover GLP-1s for obesity alone.
What about Rybelsus?
Rybelsus is oral semaglutide — same molecule in a tablet using SNAC absorption enhancer technology. Approved for type 2 diabetes (7 mg and 14 mg tablets). Significantly less effective than injected semaglutide for weight loss because oral bioavailability is only ~1%.
Can I use Ozempic for weight loss?<br />
Off-label, yes — many clinicians prescribe Ozempic for weight loss when Wegovy isn’t covered. The active ingredient is identical; only the label and pen strengths differ.
Is Wegovy stronger than Ozempic?<br />
Same drug. Wegovy’s max dose (2.4 mg) is slightly higher than Ozempic’s max (2.0 mg). The clinical trials supporting each indication used different dose ranges.
Which is cheaper?<br />
List prices are similar (~$1,300-1,500/month). Out-of-pocket cost depends entirely on insurance coverage for each indication.
Will the shortage come back?<br />
The FDA declared the GLP-1 shortage resolved in 2025. Supply is currently adequate for both Ozempic and Wegovy.